ArchivesMagazine - 12 Sep 2019Time to take profit in AstraZeneca Shares in the pharma business hit by reports of potential price controls on US drugs 12 September 2019|Great Ideas|by Tom Sieber Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email < Weighing up the future for Centrica 888 is not living up to expectations > Issue: 12 Sep 2019 - Page 14 | Contents Next: 888 is not living up to expectations Previous: Weighing up the future for Centrica Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email Tom Sieber Issue Contents Ask Tom ‘Should I reduce risk in my pension because of Brexit?’ Case study How I invest: aspiring to become an ISA millionaire Editor's View Alarming statistics show severity of profit warnings Feature Mooted changes to ‘flawed’ inflation measure could hurt investors British stocks ripe for a foreign takeover Funds Understanding two well-known fund rating systems Great Ideas The outlook is looking brighter for Synthomer Bagging bargains with Fidelity Special Values Time to take profit in AstraZeneca 888 is not living up to expectations Investment Trusts Is there more risk lurking in your portfolio than you think? News Shares in banks hit by last-minute dash for PPI claims Woodford may gauge how many investors want to sell out Weighing up the future for Centrica European airline sector is not grounded, says broker Russ Mould Donald Trump is trying to reverse 48 years of economic history Under The Bonnet How retailer Next is radically transforming its business
